Table 2.

Univariate Linear Regression Models of Serum Carboxymethyl-Lysine and Other Factors With Grip Strength

Characteristic	Beta	SE	p
Age (y)
70–74	−1.72	0.80	.03
75–79	−2.44	0.82	.003
80–84	−4.00	0.96	<.0001
85–89	−6.08	0.85	<.0001
≥90	−6.21	1.30	<.0001
White	−2.67	0.61	<.0001
Education <12 y
Body mass index (kg/m2)	0.38	0.57	.51
<18.5	0.61	1.66	.71
25.0–29.9	1.30	0.68	.06
≥30	3.90	0.67	<.0001
Mini-Mental State Examination score <24	−2.00	0.78	.01
Hypertension	1.06	0.56	.06
Coronary heart disease	0.52	0.68	.45
Congestive heart failure	−1.52	0.99	.12
Peripheral artery disease	−0.40	0.71	.57
Stroke	−0.86	1.30	.51
Osteoarthritis	−0.07	0.56	.90
Diabetes mellitus	1.39	0.78	.07
Chronic obstructive pulmonary disease	0.88	0.63	.16
Depression	−1.82	0.79	.02
Cancer	−0.37	0.90	.67
Hemoglobin A1c	0.41	0.22	.06
Serum CML, highest quartile	−1.88	0.65	.004
Serum sRAGE (ng/ml)	−0.45	0.38	.24
Serum esRAGE (ng/ml)	−2.94	1.28	.02

Note: CML = carboxymethyl-lysine; esRAGE = endogenous secretory receptor for advanced glycation end product.